| Abruzzese, Elisabetta |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Not yet recruiting | 2 | 50 | Europe | Ponatinib 15mg QD, ICLUSIG, AP24534, Ponatinib 30mg QD | Associazione Italiana Pazienti Leucemia Mieloide Cronica | Chronic Myeloid Leukemia (CML) | 10/24 | 04/25 | | |
CRU3, NCT03505554: A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma |
|
|
| Recruiting | 2 | 12 | Europe | Lorlatinib, PF-06463922 | University of Milano Bicocca, Pfizer | Anaplastic Large Cell Lymphoma, ALK-Positive | 12/24 | 12/24 | | |
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies |
|
|
| Active, not recruiting | 1/2 | 122 | Europe, US, RoW | Vodobatinib (K0706) capsules | Sun Pharma Advanced Research Company Limited | Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | 08/26 | 08/26 | | |
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation |
|
|
| Recruiting | N/A | 3000 | Europe, Canada | | University of Milano Bicocca | Chronic Myeloid Leukemia | 09/21 | 09/23 | | |
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera |
|
|
| Recruiting | N/A | 1055 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis | 05/32 | 05/32 | | |
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
|
|
| Recruiting | N/A | 319 | Europe | Ropeginterferon alfa-2b, Besremi | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Polycythemia Vera | 09/26 | 12/26 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | Europe | Therapeutic drug monitoring, Molecular Response | University of Pisa | Chronic Myeloid Leukemia, Chronic Phase | 01/24 | 12/24 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
